▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Karl Thiel

TMFBreakerThiel

Karl Thiel is a Healthcare Analyst at The Motley Fool covering biotechnology, pharmaceutical, and medical device companies. He has worked at The Motley Fool since 2004, after a brief stint co-managing a small biotech mutual fund.

Recent Articles by Karl Thiel

cover_IF

Sep 28, 2021 by Karl Thiel

Breaking Down CRISPR Technology

What investors need to know.

Dec 20, 2012 by Karl Thiel

Citron Research Short-Sells Intuitive

Apr 6, 2017 by Karl Thiel

Pacific Biosciences Has a PR Problem

PacBio is hard to break down to a sound bite, but that could spell opportunity for long-term investors.

Apr 6, 2017 by Karl Thiel

Warren Buffett's Trades: Visualizing the Oracle's Portfolio Tweaks

A look at Berkshire Hathaway's recent moves.

Nov 9, 2016 by Karl Thiel

Avoid the Shiny Happy Morons

What to look at when you're looking ahead.

Apr 6, 2017 by Karl Thiel

How I'm Saving Way More Than the Chinese

There's one easy way to take a big bite out of your expenses.

Apr 6, 2017 by Karl Thiel

Can We Save as Much as the Chinese?

This American is going to try.

Apr 5, 2017 by Karl Thiel

Want the Highest Growth?

Beta won't find it for you.

Nov 11, 2016 by Karl Thiel

Magnify Your Profits From the Bounce

Growth investing in tough times can be tough, but don't give up.

Nov 11, 2016 by Karl Thiel

Great Stocks for a Vertical World

Flat may be trendy, but there a lot of advantages to being vertical.

Apr 5, 2017 by Karl Thiel

Foolish Interview: Momenta's Craig Wheeler

The drug company is banking on a generic for blood clots and heart problems.

Nov 15, 2016 by Karl Thiel

What Is That Stock Price Telling You?

In biotech investing, it pays to close your ears to all the hubbub.

Nov 15, 2016 by Karl Thiel

The Best Drug Stock for 2007: Momenta

Swing for the fences with this drug company.

Nov 15, 2016 by Karl Thiel

Trimeris Begs for a Buyout

The pharmaceutical's reorganization plan practically posts a "for sale" sign.

Nov 15, 2016 by Karl Thiel

The Best Blue Chip for 2007: Amgen

Once a small biotech struggling to make its way in the world, Amgen has grown up.

Nov 15, 2016 by Karl Thiel

Is an HSA Right for You?

Health savings accounts can help you reduce costs -- if you know how they work.

Nov 15, 2016 by Karl Thiel

A Blueprint to Biotech Profits

Three keys to identifying promising biotech companies before the rest of the market.

Nov 15, 2016 by Karl Thiel

From Homeless to Home Free

One woman's journey should be a lesson to us all.

Mar 7, 2017 by Karl Thiel

Is an HSA Right for You?

The relatively new health savings accounts make going it alone a whole lot easier than it was a few years ago.

Nov 15, 2016 by Karl Thiel

Stock Doping

Channel stuffing in the pharmaceutical industry and elsewhere can mask the condition of a company's financials and cost investors gold.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services